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Abstract
Tumour cellularity, the relative proportion of tumour and normal cells in a sample, affects the sensitivity of mutation
detection, copy number analysis, cancer gene expression and methylation profiling. Tumour cellularity is traditionally
estimated by pathological review of sectioned specimens; however this method is both subjective and prone to error due to
heterogeneity within lesions and cellularity differences between the sample viewed during pathological review and tissue
used for research purposes. In this paper we describe a statistical model to estimate tumour cellularity from SNP array
profiles of paired tumour and normal samples using shifts in SNP allele frequency at regions of loss of heterozygosity (LOH)
in the tumour. We also provide qpure, a software implementation of the method. Our experiments showed that there is
a medium correlation 0.42 (p-value = 0.0001) between tumor cellularity estimated by qpure and pathology review.
Interestingly there is a high correlation 0.87 (p-value v 2.2e-16) between cellularity estimates by qpure and deep Ion
Torrent sequencing of known somatic KRAS mutations; and a weaker correlation 0.32 (p-value = 0.004) between IonTorrent
sequencing and pathology review. This suggests that qpure may be a more accurate predictor of tumour cellularity than
pathology review. qpure can be downloaded from https://sourceforge.net/projects/qpure/.
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Introduction
Solid tumors are comprised of a variety of cell types, including
neoplastic cells and cells which make up the stroma (e.g.
connective tissue, blood vessels and inflammatory cells). Stromal
cell contamination is a key consideration in cancer genome studies
as the sensitivity of copy number analysis, mutation detection,
cancer methylation and cancer gene expression analysis are all
confounded by increasing amounts of normal cells in a tumour [1–
3]. Accurately estimating the tumor cellularity in genomic samples
is therefore an important first step in cancer genome experiments.
Pathology review of specimens is the most common method to
estimate tumour cellularity. It is based on the reviewing of tissue
sections taken from a tumor specimen. Ideally this is carried out on
the same tissue block used for DNA extraction. In many cases,
however, the pathological review is carried out on sections well
removed from the tissue from which DNA is extracted. In this
case, irregularities in tumour shape and heterogeneity in stromal
cell contamination can confound cellularity estimates. Alternative
approaches to cellularity estimation assay the DNA sample
directly.
There are several tools that can directly estimate tumour
cellularity from single nucleotide polymorphism (SNP) microarray
data. SOMATICs was developed to identify copy number changes
in SNP microarray data and reports the percent of the sample
which contains each event, this can be used to infer tumour
cellularity, however the tool is computationally expensive and
works best in samples containing 40–75% cancer cells [4]. ASCAT
was also developed to identify copy number changes, however
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during this process ASCAT initially estimates the fraction of
aberrant or tumour cells in the sample [5]. SiDCon is a spreadsheet
based application which can determine the level of stromal
contamination [6]. Both these tools were originally developed for
SNP microarrays containing thousands of probes and lack
scalability to process current SNP microarrays with millions of
probes.
Tumor cellularity can also be estimated based on the
quantification of mutant alleles by sequencing. This approach
requires prior knowledge and careful selection of the mutation to
ensure it is an early/driver event in the cancer. In pancreatic
cancer the KRAS gene is a hotspot for somatic mutations and is
frequently mutated [7]. KRAS mutations are early events in
pancreatic cancer, thus the mutations are thought to exist in all
malignant cells. High-throughput pyrosequencing sequencing
technology is the more sensitive assay for KRAS mutation detection
compared to the dideoxy sequencing [8]. Ion Torrent sequencing
technology [9] is one of the current pyrosequencing technologies
used in our laboratory and provides faster sequencing runs and
deeper coverage compared to other approaches [10].
In this study we have developed a tumor cellularity prediction
model (qpure), which uses SNP microarray data from paired
(tumor and normal) samples to directly estimate tumor cellularity
for a given sample. This method has the advantage that the DNA
sample used to run the SNP arrays for qpure cellularity
determination is the same sample used for future genomic studies
such as sequencing. To define the model, DNA was taken from
a matched pair of normal tissue and cancer cell line and mixed at
predefined ratios to create a set of 14 standards for which the
tumour cellularity was known. The qpure method was applied to
SNP data from each of these mixtures to create a standard curve
against which other samples could be compared. We describe the
model and compare the cellularity predictions to pathology
estimates and Ion Torrent sequence data and show that the
qpure tool can accurately predict tumor cellularity.
Materials and Methods
Ethics Statement
Informed consent was obtained in written form from each
donor. Ethics approvals were granted in written form by the
medical research ethics committee of the University of Queens-
land (Project Number: 2009000745); the human research ethics
committee of Westmead Hospital (Reference Number: JH/JL
HREC2002/3/3.19 1402); the human research ethics committee
of NSW Health Western Zone (Project Number: 2006/054); the
human research ethics committee of NSW Department of Health
(Protocol Number: X11-0220 HREC/11/RPAH/329); the HAR-
BOUR human research ethics committee of Northern Sydney
Central Coast Health (Protocol Number: 0612-251M); the re-
search ethics committee of Royal Adelaide Hospital (Protocol
Number: 091107a); the human research ethics committee of
Metro South Health Service District (Reference Number: HREC/
09/QPAH/220); the human subjects research institutional review
boards of Johns Hopkins (Study Number: NA_00026689); the
human research ethics committee of South Metropolitan Area
Health Service (Reference Number: 09/324); the St John of God
Health Care Ethics Committee (Reference Number: 385); the
human research ethics committee of the Southern Adelaide Health
Service (Application Number: 167/10); the human research ethics
committee of Austin Hospital (Protocol Number: H2011/04083).
We are unable to provide a test data set as all tumor/normal
pairs processed under the aegis of the Australian ICGC effort are
subject to ICGC data release guidelines. ICGC requires that all
genomic data be lodged in public data archives including the
ICGC Data Portal (http://dcc.icgc.org/) and the European
Genome-phenome Archive (EGA, https://www.ebi.ac.uk/ega/),
however, due to ethics and privacy concerns, ICGC requires that
the public archives and all participating nations agree that no
germline data be made available without the access request being
processed through the ICGC Data Access Committee (DACO).
Many non-ICGC cancer projects operate under similar data
access restrictions and we were unable to identify an equivalent
alternative publicly available paired tumor/normal genotype and
sequencing dataset.
DNA Extraction and SNP Microarray Analysis
A total of 5 pancreatic cancer cell lines and 76 pancreatic
tumour samples were used in this study (Table S1). DNA was
extracted from samples, matched normal tissue and pancreatic cell
lines using the AllPrep DNA/RNA kit (Qiagen). 200 ng of each
DNA sample was profiled using 1 M HumanOmni-Quad
BeadChip (Illumina) following the manufacturers protocol. Chips
were scanned using an IScan (Illumina) and the B allele frequency
(BAF) and log R ratio (LRR) intensity values for each SNP
calculated using the GenomeStudio genotyping module v1.84
(Illumina).
Model Generation on Mixing Experiment
To create the qpure model a SNP microarray mixture
experiment was performed whereby DNA from a cell line and
a matched normal DNA sample from the same patient were mixed
at 14 predetermined ratios to mimic a broad range of tumour
cellularities (Table 1). The qpure cellularity prediction model
contains four major steps (Figure 1).
Step One: Select probes in regions of loss. To ensure
homozygous SNPs in the normal sample do not confound the
analysis, heterozygous SNPs from the normal sample were filtered
to select those in regions of single-copy loss in the matched tumour
sample. These SNPs should all show genotype AB in the normal
sample and either A or B in the matched tumour sample. The
DNA from any normal cell contamination within the tumour
sample reintroduces some of the lost allele and shifts the observed
allele frequency back towards genotype AB. The magnitude of the
Table 1. Design of mixing experiments.
Tumor Cellularity Sample ID Mixture
100% ND_0_CD_100 100% cell line tumor DNA
85% ND_15_CD_85 85% cell line tumor DNA
80% ND_20_CD_80 80% cell line tumor DNA
75% ND_25_CD_75 75% cell line tumor DNA
65% ND_35_CD_65 65% cell line tumor DNA
60% ND_40_CD_60 60% cell line tumor DNA
50% ND_50_CD_50 50% cell line tumor DNA
40% ND_60_CD_40 40% cell line tumor DNA
30% ND_70_CD_30 30% cell line tumor DNA
20% ND_80_CD_20 20% cell line tumor DNA
15% ND_85_CD_15 15% cell line tumor DNA
10% ND_90_CD_10 10% cell line tumor DNA
5% ND_95_CD_5 5% cell line tumor DNA
0% ND_100_CD_0 0% cell line tumor DNA
doi:10.1371/journal.pone.0045835.t001
Estimating Tumor Cellularity
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shift is directly related to the proportion of contaminating normal
cells (Figure 2). To select SNPs which show deletion of one allele in
the tumour a threshold method was employed, whereby a cutoff
value was chosen to determine the selection of the SNPs [11]. In
the qpure method, the cutoff value was calculated separately for
each sample using the median of all the selected SNPs minus the
standard deviation of middle 50% quantile.
Step Two: Determine the best possible number of
components to describe the distribution of the BAF. The
distribution of the BAF for selected SNPs in regions of loss was
determined in order to accurately identify the clusters. Two
different methods were used: a supervised clustering method k-
means clustering and an unsupervised mixture modeling method.
For a set of n observations (xi, . . . ,xn) each of which is a d-
Figure 1. Overview of the qpure method. Circos plots of the SNP array data for a paired normal (ND) and tumor (TD) sample showing regions of
LOH in the tumor sample (A). The chromosome ideograms are shown on the outer wheel, the logR and BAF values are plotted in the middle and
inner wheel respectively. The density plot of the probes in LOH regions (B) is used to calculate the d-score (C). The d-score is compared to the density
plots of probes within regions of LOH for the cell line: normal DNA mixtures which represent different cellularity (D). The d-score and cellularity are
highly correlated (E). Three plots from the left to the right are the scatter plot only, with fitting the simple linear model and with fitting the spline
regression model respectively.
doi:10.1371/journal.pone.0045835.g001
Figure 2. B allele frequency (BAF) and log R ratio (LRR) plots for a region of LOH with changing tumor cellularity. DNA from a cancer
cell line and matched normal DNA were mixed in different proportions and assayed using SNP arrays. BAF and LRR plots were generated using
GenomeStudio software (Illumina). For illustrative purposes a region of loss on the p arm of chromosome 7 in the cancer cell line is shown. In the 100
% normal sample (0% tumor) the SNPs are either heterozygous (BAF* 0.5) or homozygous (BAF= 0 or 1). In regions of single chromosome loss in
the tumour there is LOH. In the 100% cell line the BAF is showing a homozygous state and there is clear loss in the LRR. As tumour cellularity
decreases the separation of the BAF decreases.
doi:10.1371/journal.pone.0045835.g002
Estimating Tumor Cellularity
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dimensional vector, k-means clustering [12] aims to partition the
points into K clusters (C1, . . . ,CK ) so that the within-cluster







where E:E denotes Euclidean distance, and mj is the center of
cluster j which in our case can be computed as the mean of the xi
in the cluster.
Unlike the k-means clustering method, the mixture model [13]
does not require the number of clusters to be predefined. Using
either the Akaike information criterion (AIC) or the Bayesian
information criterion (BIC) the model can search for the optimal
number of clusters or partitions. For a set of n observations
(xi, . . . ,xn) that are assumed to come from a mixture of G groups






where G is the best number of clusters or partitions selected based
on AIC or BIC criteria, p is estimated from the data using the
expectation maximization algorithm, and the feature vector xi
takes the mixture density function fj(xi) in group j. By default the
mixture model by Fraley and Raftery [13] estimates the
parameters based on the optimal number of clusters in the model
as determined by BIC.
Step Three: Define the d-score that is related to tumour
cellularity. The d-score for each sample is defined as the
absolute distance between centers of the two furthest clusters.
These clusters represent SNPs that are in regions of LOH in the
tumour cells. And the d-score can be computed as
d~Dm1{mnD,
where m1 and mn represent the means of the two furthest clusters.
Step Four: Modeling the relationship between d-score and
tumour cellularity. To derive a model that could be used to
predict tumour cellularity from the d-score, both a simple linear
model and spline regression model were employed the data from
the 14 synthetic samples where the cellularity was known. Given
a set of n points (Xi,Yi), i~1, . . . ,n a simple linear regression
model can be formulated as
Yi~b^0zb^1Xiz[i,
where Xi is the d-score (see Step 3) and Yi is the cellularity. The
spline regression model [14] can be formulated as
Yi~ b^0z b^1s(Xi)z [i,
where s(:) is the smoothing function using penalized regression
splines that are designed to be optimal.
Validation of Different Predictive Models
The leave-one-out cross-validation method was used to validate
performance of the different predictive models (Table 2). These
predictive models include different combinations of clustering







where r^({i) is the cellularity estimation obtained by omitting the
ith pair (Xi,Yi).
Cellularity Estimation from Pathology and Deep-
sequencing of KRAS Mutations
Tumour cellularity was estimated by an anatomical pathologist
and sequencing of KRAS mutations was performed as an alternate
molecular measurement of tumour cellularity. Barcoded primers
were designed to amplify KRAS exon 2 and 3 (Table S2). These
exons are frequently mutated in pancreatic cancer [7] and are
known to harbor both driver/founder mutations and represent
a hot spot for somatic mutations in pancreatic cancer. Amplicons
spanning the highly perturbed codons (9,12,13,59,61) of exons 2
and 3 were generated and products were subsequently pooled and
subjected to Ion Torrent sequencing to an average depth of 5218
fold (range 609 to 21770) and 4145 fold (range 102 to 23980) in
the tumour and normal samples respectively. Identification of
somatic mutations was performed by sequence pileup and the
cellularity was calculated by determining the percentage of reads
bearing the mutation multiplied by a factor of 2 (assumes the KRAS
mutation is heterozygous).
Comparing Cellularity between Pathological Estimations,
qpure Estimations, KRAS Sequencing and ASCAT
Estimations
The correlation between pathological scores, qpure, KRAS
sequencing and ASCAT estimations was calculated either as
a Pearson’s correlation or a Spearman’s rank correlation. For
comparing the difference between two or three groups (different
estimation of tumour cellularity) either a two-sample t-test or
ANOVA test was employed.
Results
To create the qpure model SNP microarray experiments were
performed on a series of normal and cancer cell line DNAs mixed
at predetermined ratios to represent different tumour cellularites
(Table 1).
Table 2. The leave-one-out cross-validation results for each
model in the qpure method.
No Model Prediction Error
1 K-Means + Linear regression 0.5%
2 K-Means + Spline regression 0.3%
3 Mixture clustering (1:3) + Linear regression 0.2%
4 Mixture clustering (1:3) + Spline regression 0.16%
5 Mixture clustering (1:5) + Linear regression 3.4%
6 Mixture clustering (1:5) + Spline regression 2.8%
7 Mixture clustering (1:x) + Linear regression 0.2%
8 Mixture clustering (1:x) + Spline regression 0.13%
In the second column the number in the brackets is the pre-defined number of
components. The smaller prediction error is related a better prediction model.
doi:10.1371/journal.pone.0045835.t002
Estimating Tumor Cellularity
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The Relationship between Tumour Cellularity and the
Distribution of the BAF within Regions of LOH
In a normal diploid sample, SNPs occur in either a heterozygous
or homozygous state. Tumours are characterized by genomic
instability that frequently manifests itself as regions of DNA copy
number change. Loss of heterozygosity (LOH), or the loss of one
copy is a common event and manifests as regions of somatic
change of heterozygous SNPs to hemizygous SNPs. The distribu-
tion of the BAF of SNPs in regions of LOH varies with the
percentage of tumour to normal DNA in the sample (Figure 2).
The BAF distribution within regions of LOH can be presented as
two peaks which are close to the homozygous state (0 and 1) in
samples with high tumour content and which move towards the
heterozygous state (0.5) as the tumour content decreases (Figure 1D
or Figure S1).
The Relationship between Tumour Cellularity and the d-
score
We created a d-score that measures the absolute distance
between the two major BAF peaks and which can be used to
predict tumor cellularity. Two models were used to predict tumour
cellularity from the d-score: a k-means model and a mixture
model. The tumour cellularity is linearly correlated to the d-score
when the tumor cellularity is between 20–100%, but not at
cellularities v20% (Figure S2). This might be because the SNP
arrays are insensitive for very low cellularity samples or both the k-
means and mixture model are underestimating the best compo-
nents when the distribution is uni-modal for low cellularity
samples. Therefore a spline regression model was also implemen-
ted for cellularity prediction.
The stability and reliability of the d-score was tested by choosing
different log R ratio cut-off values to select probes within regions of
loss. Nine cut-off values were tested ranging from 1 percentile to
100 percentile of negative log R ratio values (Figure S3). SNPs
with log R ratio values lower than the testing cutoff values were
used in the model to estimate d-score and cellularity. The analysis
showed that the d-scores changed with the percentage of tumor
DNA in the sample, however, changing the threshold (cutoff
values) for selecting SNPs in regions of loss did not affect the d-
score significantly.
Validation of Cellularity Prediction Models
A leave-one-out cross-validation method was used to de-
termine the best model for cellularity prediction (Table 2). All
prediction models produced a prediction error (PE) of less than
5% and the mixture model without predefining the number of
cluster (1:x) with spline regression performed the best
(PE= 0.0013). The spline regression models perform best as
they not only describe the linear relationship between d-score
and the amount of tumour DNA above 20%, but also allow the
model to adjust for samples with lower amounts of tumor DNA
using the spline curve. Consequently the qpure tool has been
developed allowing for all models to be used, however the
mixture-clustering model combined with spline regression is the
default model used for cellularity prediction.
To further validate qpure, the model was used to estimate the
tumour cellularity, from SNP microarray data, of 5 pancreatic cell
lines, as cell lines are considered to be free of normal cell
contamination. The cellularity of the five pancreatic cell lines
(Table S1) were predicted as 99.8%, 100.0%, 99.5%, 100.0% and
99.9%.
Cellularity Estimation in Pancreatic Primary Tumours
DNA from a cohort of 76 primary pancreatic adenocarcinomas
was assayed using SNP microarrays and the qpure tool was used to
predict sample cellularity. The tumour cohort was also subjected
to pathological review where the sections for review were taken
from the surface of the fresh frozen tissue blocks used to isolate
tumour DNAs. Cellularity was also predicted for those tumours
bearing heterozygous KRASmutations after deep KRAS sequencing
(Table S3). The pathology, KRAS sequencing and qpure cellularity
estimates ranged from 10 to 90 percent (59+18), 7 to 83 percent
(36+19) and 12 to 72 percent (35+18), respectively. KRAS deep
sequencing and qpure estimates showed the closest concordance
(Figure 3A), with a correlation of 0.868 (p-value v 2.2e-16)
(Figure 3B). Both qpure and deep sequencing cellularity estimates
were only moderately correlated to the histological estimates:
0.421 (p-value = 0.0001) and 0.325 (p-value = 0.004) respectively
(Figure 3C and 3D). On average the pathological cellularity
estimation is about 1.7 times higher than the qpure estimation (p-
value 2.3e-13 based on a two-sample t-test).
Qpure was compared to ASCAT [5]. ASCAT estimated
cellularity for only 29 of the 76 pancreatic samples (38%) and it
ranged from 34 to 64 percent (46+8). The correlation between
ASCAT and KRAS estimations is 0.66. The ASCAT estimation
fails to converge for 47 samples, which could be due to the low
cellularity scores of those samples. The KRAS cellularity estima-
tions for the 47 samples that cannot be estimated by ASCAT
ranged from 7 to 51 percent (24+11). The pair-wise comparisons
across pathology, KRAS, qpure and ASCAT estimates are shown
in Figure S4.
Discussion
In this study we describe a tool (qpure) for estimating tumor
purity or cellularity directly from DNA samples. A key advantage
of using the qpure tool for the estimation of tumor cellularity is
that it is an unbiased statistical approach that directly measures
tumor content from the DNA sample that will be used in
downstream molecular studies. In contrast, cellularity estimates
from pathology review of histology slides are based on a tissue
section that may not be representative of the sample used for
nucleic acid extraction.
It is known that some factors such as intra-tumor heterogeneity
and tumor ploidy can confound with tumor cellularity estimation
[15]. In order to mitigate the effect of these factors on our estimate
of cellularity we applied a mixture model. Methods such as k-
means clustering require a priori knowledge of the factors
influencing the cellularity estimate; the user must pre-define the
number of clusters, or factors, before the algorithm can be applied
to the data. The advantage of using a mixture model is that it
accounts for tumour heterogeneity and tumour ploidy information
by discovering the optimal number of clusters that describe the
BAF distribution in that particular sample.
The performance of the qpure model was demonstrated using
three approaches: 1) the leave-one-out cross-validation analysis
showed that the predictive power of the qpure model is high; 2)
qpure cellularity estimates for five cell lines were all w 99%; 3)
qpure cellularity predictions were strongly correlated (0.87) with
cellularity estimates calculated from the allele frequency of KRAS
mutations detected by deep amplicon sequencing data within
a cohort of 76 pancreatic tumours. Compared to ASCAT, qpure
can predict cellularity from samples with a broad range of
cellularity levels including samples with low cellularity, while
ASCAT fails to converge for those samples. For samples that
ASCAT could process, the qpure cellularity estimates were more
Estimating Tumor Cellularity
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similar to KRAS estimates than ASCAT estimates. The correlation
of cellularity estimates by pathology and qpure within the cohort
of primary pancreatic tumours was low. This is likely because the
pathology analysis is done on a 2-dimensional section of the tissue
that may not reflect the cellularity of the sample used for nucleic
acid extraction and genomic studies. These results suggest that
qpure could be a useful tool for estimating tumor cellularity with
high accuracy and low error rate.
A limitation of the qpure method is that currently it is based on
Illumina genome-wide SNP data, however, qpure does not depend
on the resolution of the SNP array used. The model can also be
applied to other chips such as HumanOmni2.5 and Huma-
nOmni5-Quad. As long as the B Allele Frequency and log R ratio
values are provided, the tumour cellularity of the samples can be
estimated. Another requirement of the qpure method is that the
paired tumour-normal SNP data sets are used in the analysis so
that heterozygous SNPs in the normal sample can be selected.
Figure 3. Correlations of cellularity estimated by different methods in a pancreatic cancer cohort. Cellularity was predicted in the
pancreatic cohort using 3 methods: pathology review, qpure and deep Ion Torrent sequencing of KRAS. Cellularity predictions are shown in the
boxplot (A), the p-value was calculated using an ANOVA test to determine whether on average there is difference between the cellularity scores
returned by the different methods. The correlation between each method using Spearman’s rank correlation was calculated (B–D). Scatter plots are
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qpure is an effective method for estimating tumour cellularity in
samples to be used for cancer genomic studies where the presence
of normal tissue in the tumor sample can significantly affect
downstream analyses. The qpure method has been implemented
in an R package and can be downloaded from https://
sourceforge.net/projects/qpure/.
Supporting Information
Figure S1 (A) The number of normal het SNP array probes on
LOH regions in the mixture experiment. (B) The distribution of
BAF for the normal het SNPs on LOH regions in the mixture
experiment. Among 260257 heterozygous SNP probes in the
normal tissue, qpure looks for those that are in regions of LOH in
the tumour. In the mixture experiment the number of SNP array
probes was 12810, 18406, 17633, 16413, 16671, 16492, 17324,
12994, 13717, 12954, 18545, 11216, 12186 and 13004 for 100%
down to 0% respectively. Number of probes might vary in each
mixture due the threshold method used. SNP probes are identified
by qpure as present in regions of loss at 85%, 80%, 75%, 65%,
60%, 50%, 40%, 30%, 20%, 15%, 10%, 5% and 0% tumour DNA
(A). The distribution of these SNP array probes for each mixture is
shown (B).
(PDF)
Figure S2 Prediction model of tumor cellularity using d-
score in the mixing experiment. (A) fit simple linear
regression model with mixture clustering (B) fit spline regression
model with mixture clustering (C) fit simple linear regression
model with k-means clustering (D) fit spline regression model with
k-means clustering. In the plots the solid line is the fitted model
and the dash lines are its prediction intervals. The tables showed
the estimates of main parameters used in each model and the
adjusted R-squared.
(PDF)
Figure S3 D-score estimates using different thresholds
to select probes in LOH regions for samples with
different percentage of tumor DNA. The amount of tumor
DNA in the samples decreased from the left to the right. The
‘‘mycutoff’’ value is equal to the median of all the selected SNPs
minus the standard deviation of middle 50% quantile. The figure
showed that the change of cutoff value for the selection of probes
do not affect the d-score.
(PDF)
Figure S4 Pair-wise correlations between cellularity
estimates across four different methods: pathology,
qpure, KRAS sequencing and ASCAT for the 76 pancre-
atic tumour samples. As the pair-wise correlaitons get bigger
the font size gets bigger. The red line in the scatter plot showed
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